SGLT2i treatment increased the expression of connexin 43, which was accompanied by a significant shortening of the QT interval, highlighting SGLT2i as a treatment option for malignant re-entry arrhythmias in CKD [7,106]. The gene discussed is GJA1; the disease is chronic kidney disease.